Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Immunome, Inc.
< Previous
1
2
Next >
Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities
July 25, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Appoints Phil Tsai as Chief Technical Officer
June 27, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Announces Completion of Purchase of Assets from Atreca
May 20, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Announces Promotion of Max Rosett to Chief Financial Officer
May 17, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome to Present at 2024 Bank of America Healthcare Conference
May 08, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Appoints Kinney Horn as Chief Business Officer
May 02, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
April 05, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
March 28, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
March 26, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome to Participate in the Leerink Partners Global Biopharma Conference
March 07, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
March 01, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
February 20, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 16, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Announces Pricing of Public Offering of Common Stock
February 13, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Announces Proposed Public Offering of Common Stock
February 13, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
February 06, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
ADXS
IMNM
Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 05, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
January 08, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
ZNTL
Immunome Appoints Phil Roberts as Chief Technical Officer
January 04, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Appoints Carol A. Schafer to Board of Directors
January 02, 2024
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome to Acquire Antibody-Related Assets and Materials from Atreca
December 26, 2023
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome to Present at the Stifel 2023 Healthcare Conference
November 10, 2023
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Reports Third Quarter 2023 Financial Results
November 09, 2023
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Appoints Jean-Jacques Bienaimé to Board of Directors
November 08, 2023
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer
October 19, 2023
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies
October 03, 2023
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Reports Second Quarter 2023 Financial Results
August 09, 2023
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity
May 23, 2023
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit